search
APOLLO Phase 3 trial
Trends
- 1Disc Medicine to Present APOLLO Phase 3 Results for Bitopertin▼Disc Medicine to Host Webcast on APOLLO Phase 3 Topline Results for Bitopertin in EPP
Disc Medicine will host a webcast to announce topline results from its APOLLO Phase 3 clinical trial of bitopertin in erythropoietic protoporphyria (EPP), a rare light-sensitive blood disorder. The announcement of the upcoming results presentation has drawn attention from investors and the biotech community awaiting data on the drug's efficacy.
- 2Disc Medicine Shares Surge 30% Ahead of Phase 3 Trial●Disc Medicine (IRON) Shares Surge 30% Ahead of Phase 3 APOLLO Tr
Shares of clinical-stage biotech Disc Medicine jumped roughly 30% ahead of its Phase 3 APOLLO trial. The APOLLO study tests the company's lead drug candidate, bitopertin, in patients with beta-thalassemia. Investors appear to be positioning ahead of data or a key milestone in the trial, driving a sharp spike in the stock's price and trading activity.
- 3Disc Medicine Shares Jump 32% Before Phase 3 Trial●Disc Medicine (IRON) Surges 32% Premarket Ahead of Phase 3 APOLL
Disc Medicine stock rose roughly 32% in premarket trading as investors reacted to news ahead of its Phase 3 APOLLO program. The biotech, focused on blood disorder treatments, is seen as a standout mover in the healthcare space, with traders positioning for potential catalysts from the late-stage trial.